US Court Shoots Down Norwich In ‘Unprecedented’ Xifaxan ‘Skinny Label’ Claim
Delaware Court ‘Hesitant To Be The First’ To Allow Relief Claim To Proceed
Executive Summary
Coming down heavily on Norwich Pharmaceuticals, a US district court has denied the US-based generics firm’s bid for relief post-judgment in a case involving the “hotly disputed” issue of skinny label ANDA products.